Terapio is a biopharmaceutical company focused on developing therapeutics based on the RLIP76 protein. The company's initial applications include creating medical countermeasures for radiation exposure and chemical threats, targeting civilian, military, and first responder populations. The RLIP76 protein primarily operates through the oxidative stress pathway, offering benefits as both a prophylactic and post-exposure treatment. Additionally, Terapio is commercializing TPO 7630 to treat exposure to mustard compounds, an area lacking current therapies. The business model revolves around research and development of these specialized therapeutics, with revenue generated through product commercialization and potential government contracts for emergency preparedness.

Keywords: biopharmaceutical, RLIP76, radiation, chemical threats, oxidative stress, prophylactic, post-exposure, military, first responders, TPO 7630.